Статья
ТРОМБОЛИТИЧЕСКАЯ ТЕРАПИЯ ОСТРОГО ИНФАРКТА МИОКАРДА
Подчеркивается значимость тромболитической терапии как одного из методов восстановления коронарного кровотока у больных с инфарктом миокарда, рассматриваются показания и противопоказания к проведению тромболизиса, преимущества и недостатки, а также схемы введения различных тромболитиков, критерии эффективности и возможные осложнения тромболитической терапии.
1. Norris R.M., Caughey D.E., Mercer C.J., Scott P.J. Prognosis after myocardial infarction. Six-year follow-up. Br Heart J 1974:36:786-90.
2. De Vreede J.J., Gorgels A.P., Verstraaten G.M., et al. Did prognosis after acute myocardial infarction change during the past 30 years? A meta�analysis. J Am Coll Cardiol 1991;18(3): 698-706.
3. Hasai D., Begar S., Wallentin L., et al. A prospective survey of the characteristics, treatments and outcomes of patient with acute coronary syn�dromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;15:1190-201.
4. Davies M.J. The pathophysiology of acute coronary syndromes. Heart 2000;83:361-6.
5. Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M. et al. ACC/AHA Guidelines for the Management of Patients With STElevation Myocardial Infarction – Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636.
6. The ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716-22.
7. Welsh R.C., Ornato J., Armstrong P.W. Prehospital management of acute ST-elevation myocardial infarction: A time for reappraisal in North America. Am Heart J 2003;145:1-8.
8. Boersma E., Maas A.C., Deckers J.W., et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.
9. Weaver W.D., Cerqueira M., Hallstrom A.P., et al. Pre-hospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Interventional Trial. JAMA 1993;270(10):1211-6.
10. Fu Y., Goodman S., Chang W.C., et al. Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insight from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. Circulation 2001;104:2653-9.
11. Schroder R., Dissmann R., Bruggemann T., et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994;24(2):384-91.
12. Anderson D.R., White H.D., Ohman M.E., et al. Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO III trial. Am Heart J 2002;144:81-8.
13. Roux S., Christeller S., Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992;19:671-7.
14. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71- 86.
15. The Assessment of the Safety and Efficacy of a New Fibrinolytic Regimen (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with Enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001;358:605-13.
16. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-27.
17. Mehta S., Eikelboom J.W., Yusuf S. Risk of intracranial hemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet 2000; 356: 449-54.
18. Zabel K.M., Granger C.V., Becker R.C., et al. Use of bedside activated partial thromboplastin time monitor to adjust UHF dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Am Heart J 1998;136:868-76.
19. A clinical trial comparing coronary angioplasty with tissue plasminogen activator for acute myocardial infarction: the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med 1997;336:1621-8.
20. The COBALT Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction: the Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) investigators. N Engl J Med 1997;337:1124-30.
21. A comparison of reteplase with alteplase for acute myocardial infarction: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) investigators. N Engl J Med 1997;337:1118-23.
22. Mahaffey K.W., Lee K.L., White H.D., et al. Intracranial hemorrhage on the increase and beyond predicted levels: serial results from two large thrombolysis trials (abstract). Circulation 1999;100(suppl I):I-182.
23. Ferguson J.J. Highlights of the 48th Scientific Sessions of the American College of Cardiology. Circulation 1999;100:570-5.
24. Руда М.Я. Что нужно знать практическому врачу о тромболитической терапии при инфаркте микарда. Сердце 2002;(1):9-12.
25. Lee K.L., Woodlief L.H., Topol E.J., et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results From an International Trial of 41 021 Patients. Circulation 1995;91:1659- 68.
26. Califf R.M. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. Am Heart J 1999;138(suppl):S12-5.
27. Morrison L.J., Verbeek P.R., McDonald A.C., et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analy�sis. JAMA 2000;283(20):2686-92.
28. Armstrong W., Collen D., Antman E. Fibrinolysis for Acute Myocardial Infarction. Circulation 2003;107:2533-7.
29. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-14.